Sodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies.

ABSTRACT:

Objective

There is limited knowledge about severe urinary tract infections associated with SGLT2i, despite this being the basis for the Food and Drug Administration (FDA) warning. We aim to provide real-world evidence to clarify this relationship further.

Data source

A literature review was performed in PubMed and Embase for cohort studies published up to August 2024 using PICO-consistent terms.

Study selection and data extraction

Cohort studies in English involving new users of SGLT2i that compare SGLT2i with glucagon-like receptor agonists (GLP-1RA), DPP4i, and other glucose-lowering medications and report severe urinary tract infection (UTI).

Data synthesis

The random-effect model determined the odds ratio (OR) and 95% confidence interval (CI) for severe UTI

SUBMITTER: Aboukaoud M 

PROVIDER: S-EPMC12357981 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature